

Community Counts: Exploring Transcription Regulation & Immunotherapy for ES-SCLC: Tweetorial #1

References

Tweet 3

Basumallik N, Agarwal M. Small cell lung cancer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. Accessed September 29, 2021. <https://www.ncbi.nlm.nih.gov/books/NBK482458/>

Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. *Nat Rev Dis Primers*. 2021;7(1):3. doi:10.1038/s41572-020-00235-0

SEER*Explorer. An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute. Accessed October 11, 2021. <https://seer.cancer.gov/explorer/>

Tweet 4

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer (v1.2022). Updated August 9, 2021. Accessed September 29, 2021. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf

Tweet 5

ClinicalTrials.gov. Prophylactic Cerebral Irradiation or Active Magnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study) (PRIMALung). NCT04790253. Updated March 10, 2021. Accessed October 12, 2021. <https://www.clinicaltrials.gov/ct2/show/NCT04790253>

ClinicalTrials.gov. Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy. NCT04829708. Updated April 29, 2021. Accessed October 12, 2021. <https://www.clinicaltrials.gov/ct2/show/NCT04829708>

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer (v1.2022). Updated August 9, 2021. Accessed September 29, 2021. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf

Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. *N Engl J Med*. 2007;357(7):664-672. doi:10.1056/NEJMoa071780

Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2017;18(5):663-671. doi:10.1016/S1470-2045(17)30230-9

Tweet 8

HYCAMTIN® (topotecan) [prescribing information]. Novartis Pharmaceuticals Corporation. Approved 1996. Revised October 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020671s024lbl.pdf

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer (v1.2022). Updated August 9, 2021. Accessed September 29, 2021. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf

Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. *Lancet Oncol*. 2020;21:645-654. doi:10.1016/s1470-2045(20)30068-1

ZEPZELCA™ (lurbinectedin) [prescribing information]. Jazz Pharmaceuticals, Inc. Approved 2020. Revised June 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf

Tweet 9

Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. *J Clin Oncol*. 2007;25(15):2086-2092. doi:10.1200/JCO.2006.08.3998

Leary A, Gaillard S, Vergote I, et al. Pooled safety analysis of single-agent lurbinectedin versus topotecan (Results from a randomized phase III trial CORAIL and a phase II basket trial). *J Clin Oncol*. 2020;38(15_suppl):3635. doi:10.1200/JCO.2020.38.15_suppl.3635

Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. *Lancet Oncol*. 2020;21:645-654. doi:10.1016/s1470-2045(20)30068-1

Tweet 11

Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. *J Thorac Oncol*. 2020;15(4):618-627. doi:10.1016/j.jtho.2019.12.109

Ready N, Farago AF, de Braud F, et al. Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. *J Thorac Oncol*. 2019;14(2):237-244. doi:10.1016/j.jtho.2018.10.003

Tweet 12

Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. *J Thorac Oncol*. 2020;15(4):618-627. doi:10.1016/j.jtho.2019.12.109

Ready N, Farago AF, de Braud F, et al. Third-Line nivolumab monotherapy in recurrent SCLC: CheckMate 032. *J Thorac Oncol*. 2019;14(2):237-244. doi:10.1016/j.jtho.2018.10.003

Tweet 13

Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. *J Thorac Oncol*. 2020;15(4):618-627. doi:10.1016/j.jtho.2019.12.109

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer (v1.2022). Updated August 9, 2021. Accessed September 29, 2021. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf

Glossary

2L, second line
AE, adverse event
Atezo, atezolizumab
Carbo, carboplatin
Chemo, chemotherapy
CI, confidence interval
CTFI, chemotherapy-free interval
Durva, durvalumab
ES, extensive stage
Etop, etoposide
Ex, extensive-stage disease
DOR, duration of response
G-CSF, granulocyte colony-stimulating factor
HR, hazard ratio
ICI, immune checkpoint inhibitors
IO, immunotherapy
ITT, intent to treat
IV, intravenous
LS, limited stage
Lurbi, lurbinectedin
mDFS, median disease-free survival
mets, metastases
MMSE, Mini-Mental State Examination
mOS, median overall survival
mPFS, median progression-free survival
MRI, magnetic resonance imaging
NCCN, National Comprehensive Cancer Network
Nivo, nivolumab
NR, not reported
ORR, overall response rate
OS, overall survival
PCI, prophylactic cranial irradiation
PD-1, programmed cell death protein 1
PD-L1, programmed death ligand 1
PFS, progression-free survival
Pembro, pembrolizumab
PO, by mouth
PS, Performance Status scale
RT, radiation therapy
SCLC, small-cell lung cancer
Topo, topotecan
w/, with